Immuno-oncology is at the forefront of cancer research and is a leader in the global drug development pipeline. This therapeutic strategy enables the body to prevent, control, and eliminate cancer by providing the immune system with tools to discover tumors and strengthen its ability to attack cancer cells.
We understand the importance of furthering Immuno-Oncology research and developed an extensive reagent portfolio encompassing Innate Immunity (Toll-Like Receptors, STING Axis, Inflammasomes), Natural Killers, Adaptive Immunity (T-cells and CAR-T Therapies, B-cells), Immune Checkpoints, Immunosuppression, and other immune pathways. Learn more about our Immuno-oncology assays and targets in this flyer.